Articles with "weight heparins" as a keyword



Photo by siora18 from unsplash

Low molecular weight heparins and their clinical applications.

Sign Up to like & get
recommendations!
Published in 2019 at "Progress in molecular biology and translational science"

DOI: 10.1016/bs.pmbts.2019.02.003

Abstract: Heparin is an anticoagulant medication that was discovered in 1917 and used in clinic since 1935. Low molecular weight heparins (LMWHs) represent a refined use of heparin as anticoagulant medications that were developed in 1980s.… read more here.

Keywords: low molecular; heparin; molecular weight; clinical applications ... See more keywords
Photo from archive.org

Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.

Sign Up to like & get
recommendations!
Published in 2017 at "Carbohydrate polymers"

DOI: 10.1016/j.carbpol.2016.12.037

Abstract: Low molecular weight heparins (LMWHs) are produced by chemical or enzymatic depolymerization of unfractionated heparin (UFH). Besides their well-known anticoagulant effects, LMWHs have also been reported to exhibit numerous anti-inflammatory properties. Previous studies have, however,… read more here.

Keywords: low molecular; non anticoagulant; molecular weight; weight heparins ... See more keywords
Photo from archive.org

Low-molecular-weight heparins in patients with atrial fibrillation☆

Sign Up to like & get
recommendations!
Published in 2017 at "Revista Clinica Espanola"

DOI: 10.1016/j.rceng.2016.11.001

Abstract: Abstract In clinical practice, low-molecular-weight heparins are used relatively frequently in patients with atrial fibrillation to prevent embolic events. In this article, it is revised the available evidence in the following clinical situations: rapid onset… read more here.

Keywords: atrial fibrillation; low molecular; molecular weight; weight heparins ... See more keywords
Photo from wikipedia

Application of low molecular weight heparins in umbilical artery thrombosis: A case series and review of the literature

Sign Up to like & get
recommendations!
Published in 2023 at "Medicine"

DOI: 10.1097/md.0000000000033501

Abstract: Rationale: Low molecular weight heparins are widely used in various thrombotic diseases and exert a preventive effect on thrombosis in high-risk patients. Umbilical artery thrombosis (UAT) is a rare occurrence that is difficult to detect… read more here.

Keywords: weight heparins; age; molecular weight; thrombosis ... See more keywords
Photo by john_cameron from unsplash

Unfractionated Heparins, Low-Molecular-Weight Heparins, and Indirect Factor Xa Inhibitors in Plastic and Reconstructive Surgery: An Evidence-Based Review.

Sign Up to like & get
recommendations!
Published in 2023 at "Plastic and reconstructive surgery"

DOI: 10.1097/prs.0000000000010695

Abstract: SUMMARY Venous thromboembolism can present with devastating complications and sequalae, particularly in the surgical patient. Current data supports prophylactic anticoagulant use in the high-risk inpatient, defined as those with a 2005 Caprini Risk Assessment Model… read more here.

Keywords: plastic reconstructive; weight heparins; molecular weight; reconstructive surgery ... See more keywords
Photo by geraninmo from unsplash

Synthetic oligosaccharides can replace animal-sourced low–molecular weight heparins

Sign Up to like & get
recommendations!
Published in 2017 at "Science Translational Medicine"

DOI: 10.1126/scitranslmed.aan5954

Abstract: A synthetic homogeneous low–molecular weight heparin provides a safe and effective therapeutic alternative. A reliable animal-free heparin drug Full-sized and low–molecular weight heparins are widely used to treat a variety of clotting disorders. Although low–molecular… read more here.

Keywords: low molecular; heparin; animal sourced; molecular weight ... See more keywords
Photo by siora18 from unsplash

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins

Sign Up to like & get
recommendations!
Published in 2017 at "Frontiers in Medicine"

DOI: 10.3389/fmed.2017.00142

Abstract: Patients with cancer are at significantly higher risk of developing, and dying from, venous thromboembolism (VTE). The CLOT trial demonstrated superiority of low-molecular-weight heparins (LMWH) over warfarin for recurrent VTE and established LMWH as the… read more here.

Keywords: low molecular; venous thromboembolism; molecular weight; weight heparins ... See more keywords